Correspondence 0001213900-23-042639 from Augmedix, Inc. (AUGX) (CIK 0001769804)

Augmedix, Inc. (AUGX) (CIK 0001769804)
Date: May 24, 2023 · CIK: 0001769804 · Accession: 0001213900-23-042639

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-272081

Date

May 24, 2023

Author

Not clearly detected

Form

CORRESP

Company

Augmedix, Inc. (AUGX) (CIK 0001769804)

Letter

VIA EDGAR Division of Corporation Finance Attention: Rucha Pandit Re: Augmedix, Inc. Registration Statement on Form S-3 (File No. 333-272081) Request for Acceleration

Dear Ms. Pandit:

Pursuant to Rule 461 of the General Rules and Regulations of the Securities and Exchange Commission promulgated under the Securities Act of 1933, as amended, Augmedix, Inc. hereby requests that the effective date of the above-captioned Registration Statement on Form S-3, as amended, be accelerated to 4:15 p.m., Eastern Time, on May 26, 2023, or as soon as practicable thereafter.

Please contact John Rafferty of Morrison & Foerster LLP via telephone at (415) 268-6897 or via e-mail at JRafferty@mofo.com with any questions you may have. In addition, please notify Mr. Rafferty when this request for acceleration has been granted.

Sincerely,
Augmedix, Inc.

Show Raw Text

CORRESP
1
filename1.htm

Augmedix, Inc.

111 Sutter Street, Suite 1300

San Francisco, California 94104

May 24, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3720

Attention: Rucha Pandit

Re: Augmedix, Inc.

Registration Statement on Form S-3

(File No. 333-272081)

Request for Acceleration

Dear Ms. Pandit:

Pursuant to Rule 461 of the General
Rules and Regulations of the Securities and Exchange Commission promulgated under the Securities Act of 1933, as amended, Augmedix, Inc.
hereby requests that the effective date of the above-captioned Registration Statement on Form S-3, as amended, be accelerated to 4:15
p.m., Eastern Time, on May 26, 2023, or as soon as practicable thereafter.

Please contact John Rafferty of
Morrison & Foerster LLP via telephone at (415) 268-6897 or via e-mail at JRafferty@mofo.com with any questions you may have. In addition,
please notify Mr. Rafferty when this request for acceleration has been granted.

    Sincerely,

    Augmedix, Inc.

    /s/ Emmanuel Krakaris

    Name: Emmanuel Krakaris

    Title: Chief Executive Officer

cc:  Paul Ginocchio, Chief Financial Officer

    John Rafferty, Esq.

    John Owen, Esq.

SecProbe.io